NeoGenomics (NEO) Q2 FY26 earnings call

NeoGenomics delivered a strong second quarter, marked by robust clinical revenue growth and significant margin expansion, leading to an upward revision of full-year guidance. While the nonclinical Pharma segment faced headwinds, the company's strategic focus on high-value NGS testing and operational efficiencies continues to drive durable and profitable growth, with new product launches and pipeline advancements positioning it for future expansion.